Details for Patent: 11,369,590
✉ Email this page to a colleague
Which drugs does patent 11,369,590 protect, and when does it expire?
Patent 11,369,590 protects LOCAMETZ and is included in one NDA.
This patent has thirty-four patent family members in fifteen countries.
Summary for Patent: 11,369,590
| Title: | PSMA binding ligand-linker conjugates and methods for using |
| Abstract: | Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them. |
| Inventor(s): | Low; Philip Stewart (West Lafayette, IN), Kularatne; Sumith A. (West Lafayette, IN) |
| Assignee: | Purdue Research Foundation (West Lafayette, IN) |
| Application Number: | 17/359,277 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Compound; |
Drugs Protected by US Patent 11,369,590
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | LOCAMETZ | gallium ga-68 gozetotide | POWDER;INTRAVENOUS | 215841-001 | Mar 23, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | FOR USE AFTER RADIOLABELING WITH GALLIUM-68, FOR POSITRON EMISSION TOMOGRAPHY OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE LESIONS IN MEN WITH PROSTATE CANCER | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,369,590
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2008289108 | ⤷ Try a Trial | |||
| Canada | 2696627 | ⤷ Try a Trial | |||
| China | 102014956 | ⤷ Try a Trial | |||
| China | 104873982 | ⤷ Try a Trial | |||
| Denmark | 2187965 | ⤷ Try a Trial | |||
| European Patent Office | 2187965 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
